Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,354.40 +121.18 0.80%
S&P 500 1,667.47 +17.00 1.03%
Nasdaq 3,498.97 +33.72 0.97%
Ticker Volume Price Price Delta
STOXX 50 2,817.99 +11.29 0.40%
FTSE 100 6,723.06 +35.26 0.53%
DAX 8,398.00 +28.13 0.34%
Ticker Volume Price Price Delta
Nikkei 15,138.10 +100.88 0.67%
Hang Seng 23,082.70 +38.44 0.17%
S&P/ASX 200 5,180.77 +15.11 0.29%
  • Exchange: NASDAQ GS
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Medical-Drugs

VVUS:US

12.3000 USD 0.2400 1.91%

As of 20:10:00 ET on 05/17/2013.

Company Profile for Vivus Inc (VVUS)

VIVUS, Inc. is a biopharmaceutical company developing therapies for obesity, sleep apnea, diabetes and sexual health. The company markets a treatment for erectile dysfunction, and has drugs for obesity and erectile dysfunction in late-stage clinical trials.

Contact Information

Vivus Inc

1172 Castro Street
Mountain View, CA 94040
United States
Phone: 1-650-934-5200
Fax: 1-650-934-5357

Key Executives for Vivus Inc (VVUS)

Mark B LoganChairmanLeland F WilsonChief Executive Officer
Peter Y TamPresidentMichael P MillerSenior VP/Chief Commercial Ofcr
Timothy E MorrisSenior VP:Finance/CFOLee B PerryVP/Chief Accounting Ofcr
John L SlebirVP:Business Dev/Gen CnslGuy P MarshVP:US Ops/General Manager
Wesley W DayVP:Clinical Development

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil